Iza-Bren双特异性ADC治疗广泛期小细胞肺癌Ib期研究
这项开放标签、多中心、剂量扩展Ib期研究评估了靶向EGFR和HER3的双特异性抗体偶联药物iza-bren在既往系统治疗进展的广泛期小细胞肺癌患者中的疗效与安全性,52例患者中客观缓解率为48.1%,二线治疗亚组(n=22)客观缓解率达72.7%,中位无进展生存期6.2个月,中位总生存期15.0个月,常见治疗相关不良事件为血液学毒性。
要点
- iza-bren在复发广泛期小细胞肺癌中客观缓解率48.1%,中位总生存期12.2个月。
- 二线治疗亚组(n=22)客观缓解率72.7%,中位无进展生存期6.2个月。
- 常见治疗相关不良事件为中性粒细胞减少、血小板减少、贫血和白细胞减少。
核心结论
- iza-bren在复发广泛期小细胞肺癌中显示出令人鼓舞的抗肿瘤活性,尤其在二线治疗中。
- 探索性生物标志物分析提示HER3阳性表达可能与更好的治疗反应相关。
研究设计与样本
- 开放标签、多中心、剂量扩展Ib期研究(NCT05194982),纳入既往系统治疗进展的广泛期小细胞肺癌患者52例。
- 给药方案为iza-bren 2.5 mg/kg,每3周周期第1天和第8天每日一次。
- 主要终点为客观缓解率和安全性/耐受性,次要终点包括疾病控制率、缓解持续时间、无进展生存期和总生存期。
主要发现
- 总体客观缓解率为48.1%(95% CI,34.0至62.4),中位无进展生存期4.1个月(95% CI,3.0至5.5),中位总生存期12.2个月(95% CI,9.1至13.2)。
- 二线治疗患者(n=22)客观缓解率为72.7%(95% CI,49.8至89.3),中位无进展生存期6.2个月(95% CI,3.7至8.2),中位总生存期15.0个月(95% CI,8.7至未达到)。
- 最常见治疗相关不良事件为血液学毒性(中性粒细胞减少、血小板减少、贫血和白细胞减少)。
关键数值与推荐
- 客观缓解率48.1%(95% CI,34.0至62.4),疾病控制率、缓解持续时间未在摘要中报告具体数值。
- 二线治疗亚组客观缓解率72.7%(95% CI,49.8至89.3)。
临床怎么用
- iza-bren在复发广泛期小细胞肺癌尤其二线治疗中显示出较高缓解率和生存获益,支持进一步开展III期随机对照试验。
- 治疗期间需重点监测血液学毒性。
- HER3阳性表达可能作为疗效预测生物标志物,需进一步验证。
局限性
- 本研究为Ib期单臂剂量扩展研究,样本量52例,结论需III期随机对照试验验证。
- HER3表达与疗效关联为探索性分析,尚未确立为预测标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Small cell lung cancer (SCLC) remains one of the most aggressive malignancies, with limited treatment options beyond frontline chemo-immunotherapy. Izalontamab brengitecan (iza-bren, BL-B01D1) is a first-in-class bispecific antibody-drug conjugate cotargeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). We expanded the SCLC cohort to further evaluate the efficacy and safety of iza-bren in patients with extensive-stage SCLC (ES-SCLC). METHODS: This open-label, multicenter, dose-expansion phase Ib study (ClinicalTrials.gov identifier: NCT05194982) enrolled patients with ES-SCLC who had progressed on prior systemic therapies. Patients received iza-bren 2.5 mg/kg once daily on days 1 and 8 of each 3-week cycle. The primary end points were objective response rate (ORR) and safety/tolerability. Secondary end points included disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Exploratory end point included the assessment of potential associations between EGFR/HER3 expression and clinical outcomes. RESULTS: As of December 5, 2024, 52 patients were enrolled. The ORR was 48.1% (95% CI, 34.0 to 62.4), with a median PFS of 4.1 months (95% CI, 3.0 to 5.5) and a median OS of 12.2 months (95% CI, 9.1 to 13.2). In patients who received iza-bren as second-line treatment (n = 22), the ORR was 72.7% (95% CI, 49.8 to 89.3), median PFS 6.2 months (95% CI, 3.7 to 8.2), and median OS 15.0 months (95% CI, 8.7 to not reached). The most common treatment-related adverse events were hematologic toxicities (neutropenia, thrombocytopenia, anemia, and leukopenia). Exploratory biomarker analysis suggested that positive HER3 expression may be associated with better treatment response. CONCLUSION: Iza-bren showed encouraging antitumor activity in relapsed ES-SCLC, particularly in the second-line setting. A phase III randomized controlled trial of iza-bren compared with topotecan (ClinicalTrials.gov identifier: NCT06500026) is ongoing.
引用
- Zhao Y, Zhao H, Wang Q, et al. Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. J Clin Oncol. 2026. PMID: 42497381. doi:10.1200/JCO-26-00243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。